MarketPulse

enrollment protocol violations

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

Nektar Therapeutics Faces Securities Fraud Suit Over Failed Alopecia Trial Disclosure

Nektar Therapeutics faces securities fraud lawsuit over failed alopecia trial and alleged protocol disclosure violations. Stock fell 7.8% on December 16, 2025.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Nektar Therapeutics Faces Securities Lawsuit Over Trial Disclosure Claims

Rosen Law Firm urges Nektar investors to join securities class action alleging false statements about REZOLVE-AA trial enrollment. Deadline: May 5, 2026.
NKTRsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Nektar Therapeutics Faces Securities Class Action Over Misleading Trial Claims

Rosen Law Firm seeks lead plaintiffs in class action against $NKTR over alleged false statements regarding REZOLVE-AA trial enrollment. Deadline: May 5, 2026.
NKTRsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

Nektar Therapeutics Hit With Securities Fraud Lawsuit Over Failed Alopecia Trial

Nektar Therapeutics ($NKTR) faces securities fraud lawsuit after Phase 2b alopecia trial failed due to enrollment violations, triggering 7.8% stock decline.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Nektar Therapeutics Faces Class Action Over Undisclosed Trial Protocol Violations

Robbins LLP files class action against Nektar Therapeutics for allegedly concealing REZOLVE-AA trial protocol violations, triggering 7.77% stock decline after trial failure announcement.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Nektar Therapeutics Faces Securities Class Action Over Trial Enrollment Claims

Rosen Law Firm urges $NKTR investors to join class action lawsuit alleging false statements about REZOLVE-AA trial enrollment protocols caused significant shareholder losses.
NKTRsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Nektar Therapeutics Hit With Securities Class Action Over Failed Trial Disclosures

Nektar faces securities litigation over alleged misstatements about REZOLVE-AA trial enrollment practices. Stock fell 7.77% after trial failure announcement.
NKTRsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Nektar Therapeutics Faces Securities Fraud Class Action Over Failed Trial Disclosures

Schall Law Firm launches class action against $NKTR for alleged securities fraud tied to REZOLVE-AA trial protocol violations and misstatements between February-December 2025.
NKTRsecurities fraudclass action lawsuit